Entrada Therapeutics, Inc.
TRDA
$6.09
-$0.70-10.31%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -73.35M | 24.78M | 65.63M | 54.95M | 104.44M |
| Total Depreciation and Amortization | 3.91M | 3.79M | 3.77M | 3.52M | 3.41M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 11.68M | 9.95M | 7.90M | 7.55M | 7.44M |
| Change in Net Operating Assets | -66.10M | -93.06M | -118.85M | -79.98M | -129.49M |
| Cash from Operations | -123.87M | -54.55M | -41.56M | -13.97M | -14.19M |
| Capital Expenditure | -2.69M | -3.46M | -3.16M | -3.50M | -4.31M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 11.71M | -45.70M | -24.64M | -58.62M | 21.38M |
| Cash from Investing | 9.02M | -49.16M | -27.80M | -62.12M | 17.07M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2.09M | 103.12M | 102.98M | 102.26M | 102.63M |
| Repurchase of Common Stock | -11.00K | -11.00K | -11.00K | -11.00K | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2.08M | 103.11M | 102.96M | 102.25M | 102.63M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -112.77M | -599.00K | 33.61M | 26.17M | 105.51M |